Lexeo Therapeutics Past Earnings Performance
Past criteria checks 0/6
Lexeo Therapeutics's earnings have been declining at an average annual rate of -28.9%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 161.1% per year.
Key information
-28.9%
Earnings growth rate
13.5%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -161.1% |
| Return on equity | -62.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Oct 11
Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Jul 16We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Jun 18Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
Apr 09Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's
Jan 29Revenue & Expenses Breakdown
How Lexeo Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -87 | 29 | 0 |
| 30 Jun 24 | 0 | -77 | 24 | 0 |
| 31 Mar 24 | 0 | -69 | 20 | 0 |
| 31 Dec 23 | 0 | -66 | 15 | 0 |
| 30 Sep 23 | 0 | -67 | 12 | 0 |
| 30 Jun 23 | 1 | -64 | 12 | 0 |
| 31 Mar 23 | 1 | -64 | 12 | 0 |
| 31 Dec 22 | 1 | -59 | 12 | 0 |
| 31 Dec 21 | 2 | -51 | 7 | 0 |
| 31 Dec 20 | 1 | -5 | 1 | 0 |
Quality Earnings: LXEO is currently unprofitable.
Growing Profit Margin: LXEO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LXEO is unprofitable, and losses have increased over the past 5 years at a rate of 28.9% per year.
Accelerating Growth: Unable to compare LXEO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LXEO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: LXEO has a negative Return on Equity (-62.15%), as it is currently unprofitable.